Calcifediol(25-hydroxy Vitamin D3)
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
包装与价格：
| 包装 | 价格(元) |
| 5mg | 询价 |
| 10mg | 询价 |
| 25mg | 询价 |
| 50mg | 询价 |
| 100mg | 询价 |
| 250mg | 询价 |
理化性质和储存条件
| Molecular Weight (MW) | 400.64 |
|---|
| Formula | C27H44O2 |
|---|
| CAS No. | 19356-17-3 |
|---|
| Storage | -20℃ for 3 years in powder form |
|---|
| -80℃ for 2 years in solvent |
| Solubility (In vitro) | DMSO: 80 mg/mL (199.7 mM) |
|---|
| Water: <1 mg/mL |
| Ethanol: 20 mg/mL (49.9 mM) |
| Solubility (In vivo) | 2% DMSO+30% PEG 300+5% Tween+ddH2O: 5mg/mL |
|---|
| Synonyms | 25-hydroxyvitamin D3;25-hydroxy VD3; 25-hydroxy Cholecalciferol; RO 8-8892; Rovimix Hy-D; U 32070E; 25-hydroxy Vitamin D3; 25-OH Vitamin D3; Calcifediol. |
|---|
实验参考方法
| In Vitro | In vitro activity: Calcifediol induced CYP24A1 expression with EC50 at 70 nM. Calcifediol stimulated the expression of thrombomodulin with EC50 at 10-100 nM. Confocal microscopy revealed that calcifediol at 0.1 - 10 μM induced VDR translocation into the nucleus dose-dependently; the VDR localization pattern was similar in cells treated with calcitriol. |
|---|
| In Vivo | Spontaneously hypertensive rats and normotensive Wistar-Kyoto (WKY) rats were injected with either 50 ng/d calcifediol or vehicle alone for 3 days. Decreased calbindin-D9K and cellular Ca2+ flux were observed in control SHR. Calcifediol increased total cell and brush border calbindin-D9K. In contrast, Ca2+ flux, which increased in vit-D animals, remained lower in SHR for plasma calcitriol levels similar to those in WKY rats. |
|---|
| Animal model | Rats |
|---|
| Formulation & Dosage | 50 ng/d; injection
|
|---|
| References | Cardiovasc Drugs Ther. 2011 Jun;25(3):215-22; Hypertension. 1994 Aug;24(2):176-82. |
|---|
